Favourite study of #ESMO25: CCTG PR21, ¹⁷⁷Lu-PSMA-617 vs docetaxel in mCRPC

Kenrick Ng· @Kenrickng1 · X·2026-10-23 20:55· 2 天前评分70

正文 · 原文

Favourite study of #ESMO25: CCTG PR21, ¹⁷⁷Lu-PSMA-617 vs docetaxel in mCRPC
Similar efficacy, very different QoL (#ESMO26) @DKhalafMD: ✅ FACT-P stable on LuPSMA, declined on Doc ⚠️ Side-effect bother "quite a bit/very much": 15% vs 41%
Next: financial toxicity & post tx QoL

163 浏览 · 5 赞 · 3 转发 · 0 回复

会议摘要

2300TIPNCT07365995 NCT07365995 NCT07365995按 Metastatic prostate cancer 对上

BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer

https://esmocongress.esmo.org

LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：Kenrick Ng · x.com